Free Trial

Immunocore (IMCR) Competitors

Immunocore logo
$33.25 +0.84 (+2.59%)
As of 01:45 PM Eastern

IMCR vs. GRFS, TGTX, NUVL, LNTH, TLX, AXSM, AKRO, ADMA, PCVX, and KRYS

Should you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), ADMA Biologics (ADMA), Vaxcyte (PCVX), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.

Immunocore vs. Its Competitors

Grifols (NASDAQ:GRFS) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

In the previous week, Grifols had 3 more articles in the media than Immunocore. MarketBeat recorded 3 mentions for Grifols and 0 mentions for Immunocore. Immunocore's average media sentiment score of 0.71 beat Grifols' score of 0.46 indicating that Immunocore is being referred to more favorably in the news media.

Company Overall Sentiment
Grifols Neutral
Immunocore Positive

84.5% of Immunocore shares are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 10.4% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Grifols has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grifols$7.81B0.79$169.80M$1.177.68
Immunocore$310.20M5.34-$51.09M-$0.43-76.67

Grifols currently has a consensus target price of $10.30, indicating a potential upside of 14.70%. Immunocore has a consensus target price of $58.89, indicating a potential upside of 78.61%. Given Immunocore's higher possible upside, analysts clearly believe Immunocore is more favorable than Grifols.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Grifols
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00
Immunocore
1 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.55

Grifols has a net margin of 0.00% compared to Immunocore's net margin of -6.48%. Grifols' return on equity of 0.00% beat Immunocore's return on equity.

Company Net Margins Return on Equity Return on Assets
GrifolsN/A N/A N/A
Immunocore -6.48%-5.86%-2.09%

Grifols has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.

Summary

Grifols beats Immunocore on 10 of the 17 factors compared between the two stocks.

Get Immunocore News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMCR vs. The Competition

MetricImmunocoreMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.66B$2.90B$5.49B$8.93B
Dividend YieldN/A2.44%5.24%4.04%
P/E Ratio-76.6720.9327.1520.17
Price / Sales5.34191.67380.3794.17
Price / CashN/A41.7026.2128.59
Price / Book4.587.487.995.60
Net Income-$51.09M-$55.04M$3.17B$248.41M
7 Day Performance0.40%5.32%3.51%6.03%
1 Month Performance-11.49%2.44%2.80%7.70%
1 Year Performance-11.99%5.19%34.00%20.86%

Immunocore Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMCR
Immunocore
2.7203 of 5 stars
$33.25
+2.6%
$58.89
+77.1%
-12.3%$1.67B$310.20M-77.32320
GRFS
Grifols
4.0876 of 5 stars
$9.04
+2.0%
$10.30
+13.9%
+26.0%$6.09B$7.81B7.7323,822News Coverage
Analyst Upgrade
TGTX
TG Therapeutics
3.8772 of 5 stars
$35.99
-2.0%
$40.80
+13.4%
+89.3%$5.83B$329M149.96290News Coverage
NUVL
Nuvalent
3.7394 of 5 stars
$76.30
-4.2%
$119.60
+56.7%
+6.9%$5.72BN/A-17.3840
LNTH
Lantheus
4.4243 of 5 stars
$81.86
+0.5%
$130.50
+59.4%
+0.4%$5.64B$1.53B23.26700
TLX
Telix Pharmaceuticals
N/A$16.07
+0.4%
$22.00
+36.9%
N/A$5.41B$516.72M0.00N/A
AXSM
Axsome Therapeutics
4.6719 of 5 stars
$104.39
+1.0%
$172.33
+65.1%
+31.1%$5.09B$385.69M-18.09380
AKRO
Akero Therapeutics
3.431 of 5 stars
$53.36
-5.0%
$82.50
+54.6%
+140.2%$4.48BN/A-27.3630
ADMA
ADMA Biologics
4.1344 of 5 stars
$18.21
+0.3%
$27.67
+51.9%
+56.0%$4.34B$426.45M21.42530Positive News
PCVX
Vaxcyte
1.7872 of 5 stars
$32.51
-0.2%
$136.50
+319.9%
-58.9%$4.20BN/A-8.15160
KRYS
Krystal Biotech
4.4819 of 5 stars
$137.46
-1.0%
$211.13
+53.6%
-24.2%$4.01B$290.52M33.04210

Related Companies and Tools


This page (NASDAQ:IMCR) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners